Article info

Protocol
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

Authors

  1. Correspondence to Daniel Griffiths; dpg1e20{at}soton.ac.uk
View Full Text

Citation

Fennell D, Griffiths D, Eminton Z, et al
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

Publication history

  • Received March 2, 2023
  • Accepted October 30, 2023
  • First published November 22, 2023.
Online issue publication 
March 15, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.